Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Extranodal NK-T-Cell 8Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Sezary Syndrome 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Hodgkin Disease 7Burkitt Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large-Cell, Anaplastic 6Immunoblastic Lymphadenopathy 6Lymphoma, T-Cell, Peripheral 5Intraocular Lymphoma 5Melanoma 4Lymphoma, T-Cell 4Leukemia, Hairy Cell 4Multiple Myeloma 3Lymphoma 3Leukemia, Large Granular Lymphocytic 3Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2

Interventions

Rituximab 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Rituximab × Dermatologic × Clear all
NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Alexion Pharmaceuticals, Inc.

Phase 1/2 Completed
260 enrolled 33 charts
DermatologicLymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡